Feb
10
2021
0
Endeavouring to Improve Glioblastoma Multiforme Patient Prognosis – A Literature Review of Biomarkers and Novel Therapeutic Approaches
Glioblastoma Multiforme (GBM) patients typically deteriorate at a rapid rate, and survive an average of 15 months from diagnosis – despite clinical intervention with the current approach of maximal surgical resection and adjuvant chemoradiotherapy. Tumour recurrence and treatment resistance remain inevitable with this standard treatment protocol, and therefore, we must endeavour to investigate more efficacious alternatives which offer better patients better prognosis and quality of life.